Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + etoposide + vindesine
- Development stage
- Unknown
- Lead developer
- Michigan State University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Cisplatin + etoposide + vindesine is a combination chemotherapy regimen used primarily in the treatment of advanced non-small cell lung cancer (NSCLC). Cisplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks, leading to apoptosis. Etoposide is a topoisomerase II inhibitor that induces DNA strand breaks and prevents cell division. Vindesine is a vinca alkaloid that inhibits microtubule assembly, disrupting mitosis. The combination aims to exploit synergistic cytotoxic effects on rapidly dividing tumor cells. Clinical studies have shown moderate response rates and acceptable toxicity profiles for this regimen in NSCLC patients[1][2].
- Other names
- PVPVD
02
Targets
TOP2A (DNA topoisomerase II)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cisplatin + etoposide + vindesine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + etoposide + vindesine.